RecruitingNCT06243588
Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma
Sponsor
Istituto Ortopedico Rizzoli
Enrollment
400 participants
Start Date
Jan 25, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma. Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.
Eligibility
Min Age: 2 Years
Inclusion Criteria4
- Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021
- Age ≥ 2 years
- Diagnosis of Ewing Sarcoma
- Patients with available clinical and imaging data
Exclusion Criteria1
- At least one inclusion criterion not met
Interventions
OTHERclinical records review
review the medical records, radiological imaging, and histological data of these patients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06243588
Related Trials
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT0371593335 locations
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
NCT072979792 locations
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT066251901 location
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT0639510366 locations
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
NCT0654126220 locations